NCT04083079

Cost-Effectiveness Study of PEG-rhG-CSF in Prophylactic Treatment of Neutropenia After Chemotherapy in Lymphoma

Cost-Effectiveness Study of Pegylated Recombinant Human Granulocyte Colony-stimulating Factor(PEG-rhG-CSF) in Prophylactic Treatment of Neutropenia After Chemotherapy in Lymphoma

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 250 (estimated)
• Sponsor: Ruijin Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This is a pharmacoeconomic research to explore the cost-effectiveness of PEG-rhG-CSF and rhG-CSF in prophylactic treatment of neutropenia in lymphoma patients. It should provide more scientific basis for clinical decision-making.

Conditions

• Lymphoma, Non-Hodgkin
• Granulocyte Colony-Stimulating Factor
• Cost-Benefit Analysis

Interventions

Type	Name	Description
DRUG	PEG-rhG-CSF	Patients will be given PEG-rhG-CSF for primary/secondary prevention each cycle.
DRUG	rhG-CSF	Patients will be given rhG-CSF for either primary/secondary prevention or treatment once any neutropenia each cycle.

Timeline

• Start date: 2019-08-01
• Primary completion: 2021-08-01
• Completion: 2022-04-01
• First posted: 2019-09-10
• Last updated: 2019-09-10

Locations

1 site across 1 country: China